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Solid organ transplantation is a therapeutic option for end-stage organ diseases. However, complications including infection and 
graft rejection, which are related to immunosuppressive therapy, remain the major causes of morbidity and mortality following 
solid organ transplantation. The optimal approach to infection in solid organ transplant recipients is prevention; failing this, prompt 
and aggressive diagnosis and therapy are essential. In addition, the epidemiology of infections after solid organ transplantation 
has shifted as a result of changes in immunosuppressive strategies and improved survival. Immunosuppression must be linked 
with appropriate vaccinations, donor and recipient screening, patient education regarding infectious risks and lifestyle, monitor-
ing, and antimicrobial prophylaxis.
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INTRODUCTION
Solid organ transplantation is a therapeutic option for 
end-stage organ diseases. Liver, kidney, heart, and lung 
transplantations have become the standard therapy for se-
lected end-stage diseases. However, complications such as 
infection and graft rejection, which are related to im-
munosuppressive therapy, remain the major causes of mor-
bidity and mortality following solid organ transplantation.
The host response is also less effective because of the mis-
match in major histocompatibility antigens between the or-
gan donor and host, which reduces the efficacy of direct 
pathway antiviral cellular immune responses. These factors 
render the allograft susceptible to invasive viral infection.
There are 3 general timeframes during which different 
common pathogens cause infectious diseases.
Most infections occurring during the first month after 
transplantation are related to surgery and postoperative hos-
pitalization, including surgical site, lung, urinary tract, and 
indwelling device infections, and they are similar to those 
occurring in general surgical patients. After the first month, 
opportunistic infections begin to appear because of im-
munosuppression and immunomodulating viral infections 
such as cytomegalovirus (CMV) infection. Beyond the six 
months after transplantation, most patients have good trans-
plant outcome and receive minimal immunosuppression, suf-
fer from infections similar to those of the general 
population. Patients requiring high immunosuppression ow-
ing to recurrent acute or chronic rejection remain at risk 
of opportunistic infections classically observed during the 
second to sixth month after transplantation. Moreover, some 
patients may experience chronic viral infections such as 
hepatitis B or C, CMV, Epstein-Barr virus, or BK virus 
infection.
The optimal approach to infection in solid organ trans-
plant recipients is prevention; failing this, its prompt and 
aggressive diagnosis and therapy are essential. 
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BACTERIAL INFECTION
1. Clostridium difficile
Clostridium difficile is known to produce protein endo-
toxins that cause colonic mucosal inflammation and injury. 
This infection may present as diversely as fever, abdominal 
pain, and diarrhea. Antimicrobial therapy is a well-known 
risk factor for C. difficile infection.
In a retrospective study of 1932 kidney and kidney-pan-
creas transplantation patients, the overall incidence of C. 
difficile colitis was 8%, compared to 1~4% in the general 
surgery population(1).
In out setting, immunosuppression itself does not appear 
to increase C. difficile infection in kidney transplant pa-
tients(2).
Metronidazole 250~500 mg orally 3~4 times daily for 
10~14 days is considered the treatment of choice. If patients 
fail to respond to metronidazole, vancomycin 125 mg orally 
4 times daily for 10~14 days may be useful. Concerns about 
increased vancomycin resistance in other pathogens, such as 
enterococci, further discourage the use of oral vancomycin 
as the first-line therapy for C. difficile infection.
2. Mycobacterium tuberculosis
Latent tuberculosis (TB) infection can be reactivated be-
cause of immunosuppression. The infection may also be ac-
quired from donors. Most transplant centers screen for TB 
infection preoperatively(3,4).
Treatmentof TB infection is not simple, particularly when 
combined with immunosuppressive therapy. Drug inter-
actions create unique challenges, for example, cyclosporine, 
sirolimus, and tacrolimus are all substrates of cytochrome 
p450-3A isoenzymes, and a significant dose increase of 
these immunosuppressive agents may be necessary to main-
tain the therapeutic drug concentrations in the presence of 
rifampin(5,6).
VIRAL INFECTION
1. Cytomegalovirus (CMV)
Human cytomegalovirus or human herpesvirus 5 (CMV) 
belongs to the order Herpesvirales, family Herpesviridae, 
subfamily Betaherpesvirinae, genus Cytomegalovirus, and 
species Human herpesvirus 5(7). Symptomatic CMV in-
fection occurs in 20~60% of all transplant recipients and is 
a significant cause of increased morbidity and mortality in 
this population(8,9). Compared with other organ transplant 
recipients, renal transplant patients are at a lower risk of 
CMV infection, in part owing to the lower burden of latent 
virus in renal allografts. The incidence of CMV infection 
in the renal transplant population is estimated to be between 
8% and 32%(10,11). Serologic screening for antibodies to 
CMV should be performed in both donors and recipients be-
fore transplantation to identify patients who are at a risk 
of post-transplant infection and who might benefit from 
preventive strategies(12). Two strategies are commonly used 
for CMV infection prevention: (1) universal prophylaxis 
and (2) preemptive therapy. Universal prophylaxis involves 
giving antiviral therapy to all “at-risk” patients beginning 
at or immediately after transplantation for a defined time 
period. In preemptive therapy, patients are monitored at 
regular intervals for early evidence of CMV replication pri-
or to the onset of clinical symptoms by using a laboratory 
assay(13). Patients with early replication are then treated 
with antiviral therapy to prevent symptomatic disease. Each 
approach has its advantages and disadvantages that must be 
considered in the context of the patient and the allog-
raft(14). Preemptive therapy may decrease drug costs and 
toxicity. However, it requires excellent logistic coordination 
in order to obtain, receive, and act on results in a timely 
fashion; this can be difficult if patients live quite some dis-
tance from the transplant center. Prophylaxis might have 
the theoretical advantage of preventing reactivation of other 
viruses, such as human herpesvirus6 (HHV-6), and may be 
theoretically more likely to prevent the indirect effects of 
CMV infection. CMV resistance has been observed with 
both strategies. Drugs that have been evaluated for universal 
prophylaxis include acyclovir, ganciclovir, valacyclovir, val-
ganciclovir, and immunoglobulin preparations. Based on 
current data, the optimal preemptive strategy is unknown. 
Preemptive therapy is well suited for transplant recipients 
at a low or intermediate risk of CMV disease, while prophy-
laxis may be better suited for those at a high risk(15,16). 
Some studies have concluded that preemptive valganciclovir 
therapy and valacyclovir prophylaxis are equally effective 
in preventing CMV disease after renal transplantation and 
  11
Im-kyung Kim and Man Ki Ju: Opportunistic Infections after Transplantation
there is no difference in the overall costs between the two 
treatments(17,18). The same conclusions were obtained in 
studies using ganciclovir as the antiviral drug(19). A 
meta-analysis of 32 trials (3737 patients) performed to 
compare the outcomes of various prophylactic antivirals in 
transplant patients at risk of CMV disease demonstrated that 
prophylaxis decreased CMV disease, CMV infection, and 
all-cause mortality(20). This meta-analysis showed that 
ganciclovir was more effective than acyclovir in preventing 
CMV disease. Valganciclovir and intravenous ganciclovir 
were found to be as effective as oral ganciclovir for 
prophylaxis. However, ganciclovir use may be associated 
with a greater rate of CMV resistance than valganciclovir 
use, at least in the highest-risk recipients(21,22). The length 
of prophylactic treatment varies by institution but generally 
lasts for a minimum of 3 months.
Treatment of active CMV disease requires a combination 
of immunomodulation, antiviral therapy, and reduction of 
immunosuppression, if possible. The standard of care for 
treating CMV disease is 2~3 weeks of intravenous ganciclo-
vir (5 mg/kg twice daily, dose adjustments for renal dys-
function) with demonstration of clinical and virological re-
sponses to therapy. In contrast, oral ganciclovir should not 
be used to treat CMV disease because of the limited absorp-
tion and poor bioavailability. In seronegative patients and 
those with a slow response to therapy, the addition of CMV 
hyperimmune globulin (100~150 mg/kg per dose intra-
venously, administered monthly) may be useful(23). More 
recently, the introduction of valganciclovir has made possi-
ble the oral treatment of CMV disease in solid organ trans-
plant recipients. In a trial of 21 renal transplant recipients 
who had symptomatic CMV disease and viremia and were 
treated with valganciclovir, all patients cleared their in-
fection and none experienced relapse during a mean fol-
low-up of 5.5 months(24). Recently, a multicenter random-
ized controlled trial of 321 solid organ transplant recipients 
demonstrated that oral valganciclovir was not inferior to in-
travenous ganciclovir in the initial treatment of CMV vir-
emia(25). Indeed, valganciclovir was recently shown to be 
as effective as intravenous ganciclovir in the treatment of 
mild-to-moderate (i.e., nonsevere) CMV disease(26). The 
duration of treatment for CMV disease should be in-
dividualized and guided by virological and clinical 
surveillance. Viremia should be cleared before therapy is 
discontinued in order to reduce the risk of clinical relapse. 
Previous studies have shown that persistent viremia at the 
end of therapy is associated with a higher risk of disease 
relapse(27). Alternative therapies (not Food and Drug 
Administration-approved for use in solid organ transplant 
recipients) include the use of foscarnet, cidofovir, and le-
flunomide; these are reserved for treatment of antiviral 
resistance. Foscarnet is active against most ganciclovir-re-
sistant strains of CMV but has neurotoxicity and renal tox-
icity with severe magnesium wasting. Cidofovir has been 
used in renal transplant recipients; however, it often induces 
nephrotoxicity. Both foscarnet and cidofovir may exhibit 
synergistic nephrotoxicity with calcineurin inhibitors(28). 
One of the biggest challenges regarding anti-CMV treat-
ment is the emergence of antiviral resistance. Although this 
is more commonly noted in lung and pancreas transplant re-
cipients, CMV resistance to ganciclovir has also been ob-
served in renal transplant recipients. Ganciclovir resistance 
should be suspected when patients have persistent, un-
changed viremia and/or symptoms at 2 weeks into therapy, 
and in such cases, genotypic assays for the detection of mu-
tations associated with antiviral resistance should be 
performed. Treatment of resistant isolates may include the 
use of foscarnet with or without ganciclovir, or cidofo-
vir(29). Small case studies have demonstrated some efficacy 
of leflunomide for treating CMV disease in renal transplant 
patients. In a prospective study of 17 CMV-infected patients 
treated with leflunomide, 15 (88%) showed viral clearance 
and healing of infected organs(27). Other potential ther-
apeutic agents for multidrug-resistant CMV include im-
munoglobulins, leflunomide, and artesunate, although data 
supporting their use remain anecdotal(30-32). Hence, there 
is a need to identify novel agents and strategies for the man-
agement of CMV infection and disease.
2. BK virus
BK virus, a human polyomavirus, is a small DNA virus 
belonging to the human papovavirus family. The incidence 
of BK virus infection after organ transplantation is approx-
imately 2.5%, with onset usually within 1 year after trans-
plantation(33-35). The kidney is the main site of latency. 
All immunosuppressive agents can induce BK virus 
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reactivation. Clinical complications of BK virus infection in-
clude hemorrhagic cystitis, ureteral stenosis, and interstitial 
nephritis; these complications may lead to graft failure(36). 
Reduction/adjustment of immunosuppression remains the 
cornerstone in the treatment or prevention of BK nephrop-
athy(37-40). Because the reconstitution of the immune sys-
tem in the control of infection takes 4 to 12 weeks, it is 
imperative to start treatment as early as possible(41). The 
one risk encountered with immunosuppression reduction is 
the development of acute rejection. The preliminary results 
of Wali et al.(42) reflect the protocol used at the University 
of Maryland, which consists of intensive screening with sub-
sequent stepwise decrease in immunosuppression. This pro-
tocol has resulted in clearance of viremia with no graft loss 
or significant rejection diagnosed. Specifically, im-
munosuppression reduction is as follows: step 1, 50% de-
crease in the mycophenolate mofetil (MMF) dose immedi-
ately after diagnosis; step 2, 50% decrease in the target 
trough level of tacrolimus at 3 months if decoy cells persist; 
and step 3, elimination of MMF at 6 months if decoy cells 
persist. Maintenance dual therapy consists of the modified 
dose of tacrolimus and maintenance dose of prednisone (not 
exceeding 7.5~15 mg/week). In addition to decrease in im-
munosuppression, several centers have reported the use of 
several antipolyomaviral agents with anti-BK viral activity 
in vitro. These include cidofovir, leflunomide, quinolones, 
and intravenous immunoglobulin(37,40,43). 
FUNGAL INFECTION
1. Candida species
The incidence of candidal infection ranges from 5% to 
50% in transplant recipients, depending on the type of organ 
transplant(44). Pancreas and liver transplant recipients 
withRoux-en-Y anastomosis have risk factors for candidal 
infection. Use of muromonab-CD3 monoclonal antibody 
and immunomodulatory viral infections including CMV and 
HHV-6 are also factors that increase the risk of invasive 
fungal infection(45).
Universal fluconazole prophylaxis remains a controversial 
strategy in the prevention of invasive fungal infection. 
Randomized trial demonstrated deduction in candidal colo-
nization and superficial infection, but compared with oral 
nystatin, no difference in the incidence of invasive in-
fections was found(46). Fluconazole prophylaxis is recom-
mended only in high-risk patients, whereas oral nystatin or 
clotrimazole may be considered in low-risk patients(45).
Amphotericin B remains the drug of choice for candidal 
infections (0.5~0.7 mg/kg per day). However, to avoid 
nephrotoxicity,less nephrotoxic lipid formulations may be 
considered in patients who can not tolerate conventional 
agents or in transplant recipients receiving calcineurin 
inhibitors. In addition, fluconazole use may be a reasonable 
treatment alternative for Candida albicans infection(47). 
Although C. albicansis the most common Candida species 
andissusceptible to fluconazole, the incidence of infections 
caused by other Candida species resistant to fluconazole is 
rising rapidly(48).
Caspofungin, the first echinocandin, has demonstrated ac-
tivity against various Candida species(49). The combined 
use of cyclosporine and caspofungin may increase the over-
all exposure to caspofungin, thus increasing the risk of 
hepatotoxicity. On the other hand, early observations sug-
gested that the concomitant use of caspofungin with tacroli-
mus led to decreased tacrolimus concentrations(49). 
Therefore, careful drug level monitoring is necessary.
2. Aspergillus species
Invasive aspergillosis is most commonly reported in lung 
and heart-lung transplant recipients and mostly occurs with-
in 6 months after transplantation(45).
Amphotericin B is considered the first-line treatment for 
aspergillosis, but it may cause nephrotoxicity, particularly 
when the patient is receiving calcineurin inhibitors. Lipid 
formulations of amphotericin B are less likely to cause 
nephrotoxicity and can serve as substitutes, especially when 
chronic treatment is required for invasive aspergillosis(50).
Itraconazole shows activity against Aspergillus species, 
but itraconazole mono therapy is associated with higher re-
lapse rates than amphotericin Bmonotherapy. However, itra-
conazole can be used as step-down oral therapy(51). 
Voriconazole and caspofungin show activity against invasive 
aspergillosis and may be used to avoid amphotericin B neph-
rotoxicity(51). Coadministration of voriconazole and siroli-
mus is contraindicated and close monitoring of cyclosporine 
and tacrolimus levels is warranted when these azole-calci-
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neurin inhibitor combinations are used(52).
3. Pneumocystis carinii
Pneumocystis carinii pneumonia (PCP) is a common op-
portunistic infection in immunocompromised patients, in-
cluding human immunodeficiency virus patients and trans-
plant recipients. Although PCP prophylaxis is a routine 
practice, the drug regimen and therapy duration vary de-
pending on the transplant center and type of organ trans-
planted(53). Trimethoprim-sulfamethoxazole provides ex-
cellent prophylaxis against PCP. Pentamidine (300 mg in-
halation monthly) or dapsone (50~100 mg orally once dai-
ly) may also be used.
OTHER INFECTIONS
1. Toxoplasmosis
Toxoplasma gondii infection is of the greatest concern 
among heart transplant patients, but infection can occur in 
other types of transplant recipients, including kidney and 
liver recipients(54,55). Toxoplasma organisms can remain 
encysted within muscle tissue, such as cardiac muscle. Thus, 
infection is acquired as a result of the reactivation of cysts 
that remain dormant in the donor hearts of tox-
oplasma-seronegative children. Clinical manifestations can 
occur as early as 2 weeks after transplantation. Manifesta-
tions include pneumonia, fever syndrome, myocarditis, cho-
rioretinitis, and central nervous system disease. Current pro-
phylaxis includes pyrimethamine/sulfadiazine for donor 
(+)/recipient (-)patients. Trimethoprim-sulfamethoxazole is 
typically used in Recipient (+) patients. However, some ex-
perts also recommend trimethoprim-sulfamethoxazole for 
donor (+)/recipient (-)patients. The duration of prophylaxis 
is usually 6 months.
CONCLUSION
The epidemiology of infections after solid organ trans-
plantation has shifted as a result of changes in immuno-
suppressive strategies and improved survival. Immunosu-
ppression must be linked with appropriate vaccinations, do-
nor and recipient screening, patient education regarding in-
fectious risks and lifestyle, monitoring, and antimicrobial 
prophylaxis. The risk of infections has increased with the 
use of lymphocyte-depleting agents. Some drugs that alter 
the mobilization of lymphocytes (e.g., FTY720, a high-af-
finity agonist of sphingosine 1-phosphate receptor-1) or 
other components of the inflammatory response may alter 
the histology of infection and further confound diagnosis. 
Thus, it should be anticipated that with the introduction of 
each new immunosuppressive agent, there could be unique 
effects on the presentation and epidemiology of infection 
in organ transplant recipients.
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